Search clinical trials for: ASP2409

Total 17 results

Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects

Healthy Subjects | Pharmacokinetics of ASP2408

United States
Astellas Pharma Inc

Completed

A Study to Evaluate the Safety of ASP2408 After Subcutaneous Administration to Healthy Male Subjects

Healthy | Pharmacokinetics of ASP2408

Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections

Healthy Subjects | Pharmacokinetics of ASP2408

United States
Astellas Pharma Europe B.V.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205

Healthy Subjects | Pharmacokinetics of ASP2205

United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis | Pharmacokinetics of ASP2409

United States
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States, France, Italy, United Kingdom
Astellas Pharma Global Development, Inc.

Not yet recruiting

A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

B-cell Lymphoma
Astellas Pharma Global Development, Inc.

Completed

A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis | Pharmacokinetics of ASP2408

United States
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites

Allergic to House Dust Mites

Germany
Astellas Pharma Global Development, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects

Healthy Volunteers | Pharmacokinetics of ASKP1240

United States
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Antisoma Research

Completed

Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma

Metastatic Renal Cell Carcinoma | Metastatic Malignant Melanoma

United Kingdom, New Zealand
Cumberland Pharmaceuticals

Completed

A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

Kidney Diseases | End Stage Renal Disease

United States
Astellas Pharma Europe Ltd.

Completed

Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) (PROFILE)

Inflammatory Bowel Disease (IBD) | Clostridium Difficile Infection (CDI)

Austria, France, Greece, Italy, Poland, Russian Federation, United Kingdom
Astellas Pharma Europe Ltd.
Merck Sharp & Dohme LLC

Completed

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population (EXTEND)

Clostridium Difficile

Greece, Spain, Russian Federation, Denmark, Austria, Belgium, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Slovenia, Sweden, Switzerland, Turkey, United Kingdom
Astellas Pharma S.A.S.

Completed

Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE)

Clostridium Difficile Infection

France
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States

3

Subscribe